KDM2/7-IN-2

KDM2/7-IN-2 (Compound 183c) (3.5-10 μM; 1.5-4 weeks) selectively inhibits the proliferation of ALT-positive human cancer cell lines including SAOS2 in colony formation assays, while exerts weak effects on ALT-negative cell lines^[1].
KDM2/7-IN-2 (11-14 days) potently inhibits the proliferation of ALT-positive SAOS2 human osteosarcoma cells in continuous growth assays, with an IC₅₀ of 3 nM^[1].
KDM2/7-IN-2 (10 μM; 3 days) induces an E2F-mediated core repressive transcriptional program in SAOS2 and SJSA1 cells, while triggering distinct adaptive responses: global downregulation of key functional pathways occurs in SAOS2 cells, whereas compensatory survival pathways are activated in SJSA1 cells, which may explain the differential sensitivity of the two cell lines to this compound^[1].
KDM2/7-IN-2 (10 μM; 6 days) inhibits KDM2A activity in SJSA1 cells, increasing genome-wide H3K36me2 levels by approximately 4-fold^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.